This ETF offers much more of a mid-cap tilt than other health-care ETFs. As such, we believe it provides purer exposure to the U.S. health-care sector than do some of its peers, whose holdings include large-cap pharmaceutical companies with meaningful overseas businesses.
Given litigation worries in the health-care sector, an ETF is an effective vehicle for diversifying away much of the company-specific risk.
The health-care exchanges are expected to provide modest benefits at a minimum to several important health-care subsectors, including pharmaceutical firms, health-care providers, MCOs, and PBMs. Read more